Steven Jon Russell Sells 4,221 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Steven Russell sold 4,221 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the completion of the sale, the insider directly owned 169,628 shares in the company, valued at approximately $3,241,591.08. This represents a 2.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Price Performance

Beta Bionics stock opened at $19.42 on Friday. The firm has a market capitalization of $873.71 million, a P/E ratio of -11.77 and a beta of 3.37. The stock has a fifty day moving average price of $17.17 and a two-hundred day moving average price of $13.65. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, equities research analysts predict that Beta Bionics, Inc. will post -2.1 EPS for the current fiscal year.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BBNX. UBS Group initiated coverage on Beta Bionics in a report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 target price on the stock. Bank of America cut their price objective on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. The Goldman Sachs Group boosted their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Truist Financial raised their target price on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, William Blair began coverage on Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating for the company. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its holdings in Beta Bionics by 306.1% during the 2nd quarter. California State Teachers Retirement System now owns 8,556 shares of the company’s stock worth $134,000 after buying an additional 6,449 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Beta Bionics during the second quarter worth $8,566,000. Man Group plc bought a new stake in shares of Beta Bionics during the second quarter worth $419,000. Legal & General Group Plc acquired a new position in shares of Beta Bionics during the second quarter valued at $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics in the second quarter worth about $172,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.